Not yet recruiting
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
NCT07816237· Phase 3· Bisirna Therapeutics (Suzhou) Co., Ltd.· Source
Contact: Hongyan Tong
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Contact: Weidong Li, MD
Not yet recruiting
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Jie Jin
Not yet recruiting
Early Lumbar Drainage for Intraventricular Hemorrhage
NCT07625449· Second Affiliated Hospital of Nanchang University· Source
Contact: The First Affiliated Hospital of Zhejiang University School of
Recruiting
DEC003M in Prostate Cancer
NCT07657806· Phase 1· Hangzhou DAC Biotechnology Co., Ltd.· Source
Contact: Dan Xia, MD (Doctor of Medicine)
Not yet recruiting
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
NCT07729917· Phase 2· Zhejiang University· Source
Contact: Yiwen Chen
Recruiting
A Study of Metformin to Improve Cardiac Function After LVAD Implantation
NCT07666698· Phase 1/2· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source
Contact: Pan, Dr.
Recruiting
A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
NCT07635186· Phase 2· Ausper Biopharma Co., Ltd.· Source
Contact: Lu
Recruiting
A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
NCT07593027· Phase 1/2· ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.· Source
Contact: Xiaogang Guo
Recruiting
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
NCT07483554· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Contact: Tingbo Liang
Recruiting
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
NCT07240766· Phase 2· Zhejiang University· Source
Contact: Yiwen Chen, MD.
Active, not recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263· Phase 2· Takeda· Source
Recruiting
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
NCT07761533· Phase 1/2· Chaser Therapeutics, Inc.· Source
Contact: Yiming Zhu
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686· Phase 2· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Jie Jin
Recruiting
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
NCT07183878· First Affiliated Hospital of Zhejiang University· Source
Contact: Yanmin Zhao, MD
Recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
NCT06871228· Beijing Anzhen Hospital· Source
Contact: Xiaogang Guo
Recruiting
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
NCT06770439· Phase 2· Zhejiang University· Source
Contact: Yiwen Chen
Active, not recruiting
Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria
NCT06848296· Phase 1· Bisirna Therapeutics Pte. Ltd.· Source
Not yet recruiting
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840· Phase 2· Betta Pharmaceuticals Co., Ltd.· Source
Contact: Wanlin Chen, Master
Not yet recruiting
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
NCT06902025· He Huang· Source
Contact: He Huang, PhD
Recruiting
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
NCT06770452· Phase 2· Zhejiang University· Source
Contact: Yiwen Chen
Not yet recruiting
Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
NCT06848920· Phase 2· Zhejiang University· Source
Contact: Qiangfeng Wang
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Recruiting
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
NCT07003737· First Affiliated Hospital of Zhejiang University· Source
Contact: Hengwei Wu
Recruiting
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
NCT06852807· First Affiliated Hospital of Zhejiang University· Source
Contact: Xinhui Su, MD
Not yet recruiting
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
NCT06672263· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: ZhenFang Liu, Doctor
Recruiting
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT06571825· Phase 4· He Huang· Source
Contact: Yanmin Zhao, PhD
Recruiting
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292· Phase 3· Ascentage Pharma Group Inc.· Source
Contact: Jie Jin, M.D.
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Wenjuan Yu
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
NCT06241846· Phase 2· MediLink Therapeutics (Suzhou) Co., Ltd.· Source
Contact: Coordinator Clinical operation director
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637· Phase 1/2· Evopoint Biosciences Inc.· Source
Contact: Yingjie zhao Yingjie Zhao
Active, not recruiting
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841· Phase 2· Shanghai Ming Ju Biotechnology Co., Ltd.· Source
Recruiting
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
NCT06043466· Phase 1· Chongqing Precision Biotech Co., Ltd· Source
Contact: Weijia Fang, MD
Not yet recruiting
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892· Phase 3· Suzhou Puhe Pharmaceutical Technology Co., LTD· Source
Contact: Jianya Zhou
Active, not recruiting
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752· Phase 1· MediLink Therapeutics (Suzhou) Co., Ltd.· Source
Recruiting
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270· Phase 2· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Tingbo Liang
Active, not recruiting
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· Phase 2/3· Biogen· Source
Active, not recruiting
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231· Phase 1/2· Amgen· Source
Active, not recruiting
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484· Phase 3· ADC Therapeutics S.A.· Source